Table 3.
Multivariable analysis for predicting overall survival after adjustment for age and sex.
| Variables | Model 1 | Model 2 | ||
|---|---|---|---|---|
| p-Value | Hazard Ratio (95% CI) |
p-Value | Hazard Ratio (95% CI) |
|
| Clinical TNM stage | ||||
| Stage III | 0.042 | 1.98 (1.02–4.69) | 0.177 | 1.82 (0.76–4.36) |
| Stage IV | 0.005 | 4.71 (1.59–13.95) | 0.001 | 5.66 (2.26–15.64) |
| NLR | 0.835 | 1.11 (0.41–2.98) | 0.751 | 1.17 (0.44–3.10) |
| BM SUV | 0.005 | 4.30 (1.57–11.76) | 0.003 | 5.17 (1.76–15.16) |
| TLG | 0.037 | 2.37 (1.08–5.97) | 0.028 | 2.78 (1.12–6.95) |
| First-order entropy | 0.013 | 2.89 (1.29–6.01) | - | - |
| GLCM energy | - | - | 0.379 | 0.84 (0.25–1.81) |
| GLZLM zone length nonuniformity | - | - | 0.751 | 1.89 (0.55–6.47) |
BM, bone marrow; CI, confidence interval; GLCM, grey-level co-occurrence matrix; GLZLM, grey-level zone length matrix; NLR, neutrophil-to-lymphocyte ratio; SUV, standardized uptake value; TLG, total lesion glycolysis.